Category: Covid-19

Page 11234..1020..»

Updated COVID vaccines are coming soon – NPR

August 22, 2024

A new round of COVID-19 vaccines will be rolled out soon. Scott Olson/Getty Images hide caption

The Food and Drug Administration is expected to green light new COVID-19 vaccines any day now to help people protect themselves from the latest strains of the virus.

The new COVID vaccines are designed to keep the shots up to date with the virus, which keeps evolving to evade our immune systems.

The new formulations cover the variants that have been circulating more recently, Dr. Peter Marks, who runs the FDA Center for Biologics Evaluation and Research, tells NPR. So the hope is that the closer we match the strain, the better protection one will have, and perhaps the longer the protection well have.

The Pfizer-BioNTech and Moderna mRNA vaccines expected to get the go-ahead this week target the KP.2 variant. The Novavax vaccine, which is based on an older technology, targets an earlier strain called JN.1.

Both target strains have already been overtaken by even newer variants, but theyre all still part of the omicron group. The hope is the vaccines are close enough to boost immunity and protect people through the rest of the surprisingly big summer wave and the surge expected this winter.

The vaccine is not intended to be perfect. Its not going to absolutely prevent COVID-19," Marks says. "But if we can prevent people from getting serious cases that end them up in emergency rooms, hospitals or worse dead thats what were trying to do with these vaccines.

The new vaccines should cut the risk of getting COVID by 60% to 70% and reduce the risk of getting seriously ill by 80% to 90%, Marks says. The shots are expected to become available as soon as this weekend to anyone age 6 months and older.

Right now were in a wave, so youd like to get protection against whats going on right now, Marks says. So I would probably get vaccinated in as timely a manner as possible. Because right now the match is reasonably close. Youre probably going to get the most benefit youre going to get from this vaccine against whats currently circulating. So when this gets into pharmacies I will probably be on line as soon as it gets rolled out.

To maximize the chances of getting the best protection, people should wait at least two or three months since their last bout of COVID or their last shot to get one of the new vaccines, Marks says.

Some people could consider waiting until September or October if theyre especially concerned about maximizing protection through the winter surge and over the holidays.

Getting vaccinated sometime in the September to early October time frame seems like a pretty reasonable thing to do to help bring you protection through the December/January time frame, says Marks. It doesnt, like, suddenly stop. This is not like something that suddenly cuts off at three or four months. Its just that the immunity will decrease with time.

In my opinion, everyone should get one of the new vaccines, says Dr. George Diaz, chief of medicine at Providence Regional Medical Center Everett in Everett, Wash., and a spokesperson for the Infectious Disease Society of America. Being vaccinated yourself will prevent transmission to other people. So that will help reduce the spread of the disease in the community, especially to the most vulnerable people. So youre not just helping yourself but also helping others.

In addition, getting vaccinated reduces the risk for long COVID, Diaz adds.

Others question whether everyone necessarily needs another shot, arguing most younger healthy people still probably have enough immunity from all the shots and infections theyve already gotten to protect them from getting really sick.

Anyone who wants to get this vaccine should get it, says Dr. Paul Offit, a vaccine expert at the University of Pennsylvania who advises the FDA. It certainly makes sense why someone would want to get it because it lessens your chance of getting a mild or moderate infection for about four to six months and to some extent lessens your chances of spreading the virus. But the calculation could be different for younger people. Were I a 35-year-old healthy adult whod already had several doses of vaccine and one or two natural infections I wouldnt feel compelled to get it, Offit says.

And regardless of the public health advice, its far from clear how many people will want one of the new shots. Only about 22% of eligible adults got one of the last ones.

But for anyone who does want the COVID vaccine, they can get the flu shot at the same time. In addition, federal officials are recommending anyone age 75 and older also get one of the new vaccines to protect against the respiratory syncytial virus, or RSV. Same goes for pregnant people and those ages 65 to 74 who are at high risk of getting seriously ill from RSV.

Older at-risk people will probably be able to get a second shot with the new COVID vaccines in the spring or early summer to help protect them against another wave next summer.

Insured people can get all three vaccines for free if they get their shot from an in-network provider. But a federal program that paid for the vaccines for uninsured adults expired.

In the public health community were very concerned about how they will access protection and looking for ways for how were going to solve that problem, says Dr. Kelly Moore, who runs Immunize.org, an advocacy group. We know that the people who are uninsured are the least likely to be able to afford becoming ill missing work, staying home from school.

Go here to read the rest:

Updated COVID vaccines are coming soon - NPR

A COVID-19 wave has surged in all US regions. Know the symptoms and new variant – USA TODAY

August 22, 2024

usatoday.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.

Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on usatoday.com

Continue reading here:

A COVID-19 wave has surged in all US regions. Know the symptoms and new variant - USA TODAY

Not Joe Bidens DNC: 6 takeaways so far. Plus, new COVID-19 vaccines on the way – NPR

August 22, 2024

Up First briefing: Tim Walz DNC speech; COVID-19 vaccines Tim Walz stepped into the spotlight last night at the DNC giving the crowd a pep talk. Here are five other takeaways from the convention so far. And, new COVID-19 vaccines are on the way.

Good morning. You're reading the Up First newsletter.Subscribehere to get it delivered to your inbox, andlistento the Up First podcast for all the news you need to start your day.

NPR's senior political editor/correspondentDomenico Montanaro joins the newsletter today to break down the DNC so far:

Gov. Tim Walz of Minnesota, Kamala Harris' vice-presidential pick, stepped into the spotlight on night three of the Democratic National Convention in Chicago and he gave the crowd a pep talk, as Democrats tried to make a broad appeal. Here are six takeaways from the DNC so far:

Democratic vice presidential nominee Minnesota Gov. Tim Walz reacts with his daughter Hope Walz after accepting the Democratic vice presidential nomination on stage during the third day of the Democratic National Convention. Win McNamee/Getty Images hide caption

Stay informed during the 2024 election season and beyond by subscribing to the NPR Politics newsletter and listening to the NPR Politics podcast.

Harris will close out the DNC tonight, formally accepting the Democratic Partys presidential nomination. Shell also lay out her vision for the country. Harris short campaign has allowed her to build momentum while saying less than most candidates have about how they would govern. Over the last four years, as vice president, President Bidens policy agenda has also been hers. Now, she has the ability to navigate major issues with a little more authority.

New COVID-19 vaccines that might combat the latest virus strains are expected to be approved any day now by the Food and Drug Administration. The new vaccines have been reformulated to stay up to date with the virus, which keeps evolving to evade our immune systems. The Pfizer-BioNtech and Moderna vaccines target the K-P-2 variant. The Novavax vaccine targets an earlier strain called JN.1. Both target strains have already been overtaken by newer variants, but the hope is the vaccines are close enough to boost immunity and protect people through the rest of the summer wave and the surge expected this winter. Dr. Peter Marks, who runs the FDA Center for Biologics Evaluation and Research, tells NPR the new vaccines could cut the risk of getting COVID by 60% to 70% and reduce the risk of getting seriously ill by 80% to 90%.

The federal investigation into Diamond Shruumz products hasn't yet pinned down what's responsible for the illnesses. Preston Gannaway/for NPR hide caption

Dr. Michael Moss couldnt explain why an ICU patient was convulsing after eating a mushroomed-infused candy bar. Moss, a toxicologist at the University of Utah Hospital, began contacting poison centers across the country for help. He discovered similar cases were popping up: Patients with nausea, vomiting, agitation, seizures, loss of consciousness and other symptoms. There are now 130 documented illnesses including two suspected deaths all tied to the same brand of mushroom edibles, called Diamond Shruumz, according to the Food and Drug Administration. The edibles maker said it has ceased production and distribution of the products, citing toxic levels of muscimol, the compound found in Amanita muscaria, the mushroom used to make the edible. But its still not clear that the mushroom is to blame for the illnesses.

Abby Ingwersen works on a client at Nice Try Tattoo in New York. Mengwen Cao for NPR hide caption

Young tattoo artists are challenging the traditional ways of running a business and how they poke ink into skin. Theyre working to leave a permanent mark, from forming independent collectives to reviving the stick and poke method that uses a singular needle to etch designs. Independent studios like these rose during the pandemic, pushing styles and tastes to evolve, but the goal has remained the same: To create distinctive, meaningful, permanent art.

Independent Presidential Candidate Robert F. Kennedy Jr. announced attorney, tech entrepreneur and philanthropist Nicole Shanahan to the Kennedy campaign as his vice presidential running mate during an event in Oakland, Calif., on March 26. Anadolu via Getty Images hide caption

Independent Presidential Candidate Robert F. Kennedy Jr. announced attorney, tech entrepreneur and philanthropist Nicole Shanahan to the Kennedy campaign as his vice presidential running mate during an event in Oakland, Calif., on March 26.

This newsletter was edited byObed Manuel.

Go here to see the original:

Not Joe Bidens DNC: 6 takeaways so far. Plus, new COVID-19 vaccines on the way - NPR

Iowa sees rise in COVID-19 cases as part of national trend – Des Moines Register

August 22, 2024

desmoinesregister.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.

Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on desmoinesregister.com

Read the original:

Iowa sees rise in COVID-19 cases as part of national trend - Des Moines Register

Severe COVID Linked to Mental Illness in Weeks, Months After Infection – Medpage Today

August 22, 2024

Severe COVID-19 was associated with elevated risks for depression and serious mental illness months after infection, especially among unvaccinated people, a cohort study involving more than 18 million individuals in the U.K. found.

Compared to the period before a COVID infection or to individuals without an infection, those hospitalized for COVID had substantially higher risks for depression in the 4 weeks after admission, both in the pre-vaccine era (adjusted hazard ratio [aHR] 16.3, 95% CI 15.6-17.0) and among unvaccinated (aHR 15.6, 95% CI 13.9-17.4) and vaccinated (aHR 12.9, 95% CI 12.0-14.0) individuals in the vaccine era. In all three groups, the risk for depression remained elevated up to a year later.

Similarly, elevated risks for serious mental illness were observed among hospitalized patients in the 4 weeks after a COVID diagnosis, reported Jonathan Sterne, PhD, of the University of Bristol in England, and colleagues in JAMA Psychiatry:

Rates of most mental illnesses examined -- including anxiety, post-traumatic stress disorder, eating disorders, addiction, and self-harm -- were higher in the first 4 weeks after a COVID hospitalization.

"The main surprise was that the association of COVID-19 with subsequent mental ill-health appeared restricted to severe COVID-19 that led to hospitalization," Sterne told MedPage Today. "There was little association of COVID-19 that did not lead to hospitalization with subsequent mental ill health."

Serious mental illness was a composite of schizophrenia, schizoaffective disorder, bipolar disorder, and psychotic depression.

Vaccination may attenuate adverse effects of COVID on mental illnesses, the authors posited. "Potential mechanisms include reduced systemic inflammation and psychological benefits of vaccination, such as reduced concern about COVID-19 and increased social engagement," they wrote.

"The main benefit of COVID-19 vaccination is that it provides substantial protection against severe COVID-19. Therefore, our findings underscore the importance of COVID-19 vaccination, particularly in groups at highest risk of severe COVID-19," Sterne emphasized.

"Serious mental illnesses are associated with more intensive healthcare needs and longer-term health and other adverse effects, and so longer-term monitoring for onset of new mental illnesses among patients hospitalized because of COVID-19 may be justified," he added.

Regardless of whether patients with COVID were hospitalized, in the pre-vaccine era the overall risk of depression in the 4 weeks after infection was 93% higher (aHR 1.93, 95% CI 1.88-1.98) than before or without COVID. The overall risk of developing serious mental illness was 49% higher (aHR 1.49, 95% CI 1.41-1.57). Among those who remained unvaccinated, the overall risks of depression (aHR 1.79, 95% CI 1.68-1.90) and serious mental illness (aHR 1.45, 95% CI 1.27-1.65) were also elevated.

Incidence of depression up to 28 weeks later and of serious mental illness across all time periods was greater in people 60 years and older, which may reflect increased risk for severe disease as well as anxiety about severe outcomes, the authors pointed out.

Of note, incidence of mental illnesses remained elevated for more than 28 weeks after a COVID-19 diagnosis. The estimated excess risk of depression at 28 weeks after COVID was 1,033 per 100,000 people in the pre-vaccine era and 1,008 per 100,000 in the unvaccinated group, whereas the risk among vaccinated people was less than half that, at 451 per 100,000.

The trend for serious mental illness at 28 weeks was similar, with an estimated excess risk of 235 and 209 per 100,000 in the pre-vaccine era and among the unvaccinated, respectively, versus 53 per 100,000 in the vaccinated group.

The study analyzed data from three cohorts during the pre-vaccine (January 2020 to June 2021) and vaccine eras (June to December 2021; the Delta variant period):

The average ages of the pre-vaccine and vaccinated cohorts were 49 and 53, respectively, and about half were female. The average age of the unvaccinated cohort was 35 years and about 42% were female. Diagnoses of COVID were confirmed by test results, by a general practitioner, or from hospital or death records.

The authors acknowledged several limitations to the study. Unvaccinated people may have been less likely to test for COVID or use health services, with a possible underestimation of effects. Conversely, people with a diagnosis of COVID and related hospitalization may have been more likely to be diagnosed with mental illness in a hospital setting. It is also possible that the mental health effects observed were not unique to infection with SARS-CoV-2.

Katherine Kahn is a staff writer at MedPage Today, covering the infectious diseases beat. She has been a medical writer for over 15 years.

Disclosures

The study was supported by the COVID-19 Longitudinal Health and Wellbeing National Core Study, which is funded by the Medical Research Council and the U.K. National Institute for Health and Care Research (NIHR).

Sterne reported grants from the NIHR, the U.K. Research and Innovation (UKRI) Medical Research Council, and Health Data Research U.K. Co-authors reported relationships with AstraZeneca, the Bennett Foundation, the Wellcome Trust, NIHR Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley, the Mohn-Westlake Foundation, the National Health Service England, Induction Healthcare, UKRI, and Health Data Research U.K.

Primary Source

JAMA Psychiatry

Source Reference: Walker VM, et al "COVID-19 and mental illnesses in vaccinated and unvaccinated people" JAMA Psychiatry 2024; DOI: 10.1001/jamapsychiatry.2024.2339.

Originally posted here:

Severe COVID Linked to Mental Illness in Weeks, Months After Infection - Medpage Today

COVID-19 is surging and you can’t find a booster? You’re not alone. – USA TODAY

August 22, 2024

usatoday.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.

Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on usatoday.com

Follow this link:

COVID-19 is surging and you can't find a booster? You're not alone. - USA TODAY

COVID-19 and mpox cases on the rise in Northeast Ohio – News 5 Cleveland WEWS

August 22, 2024

CLEVELAND Mpox has been declared an international emergency by the World Health Organization. A mpox variant has been rapidly spreading across parts of Africa. Doctors warn local cases are rising, too.

As of Aug. 15, there are currently 459 cases of mpox across Ohio, with Cuyahoga County leading the number with 174 cases. While experts said this outbreak shouldnt cause COVID-like lockdowns, testing must be ramped up, and vaccinations must continue for at-risk communities.

Mpox is a highly contagious viral disease that can cause flu-like symptoms and painful skin lesions. It often spreads through close physical contact. A new strain of the mpox virus has been surging in Africa over the past few months, leading the World Health Organization to declare an international health emergency. This is the second time mpox has been declared an international emergency recently. The first was in 2022, when mpox sickened nearly 32,000 Americans, according to the Centers for Disease Control and Prevention.

Mpox is a little bit different from chickenpox and smallpox, said Dr. Amy Edwards, infectious disease specialist at UH Rainbow Babies and Childrens Hospital. Smallpox, there tends to be more of them. Mpox is a little more sparse, but the difference between smallpox and chickenpox is chickenpox typically has ones that are different ages.

According to the Ohio Department of Health, five people in the state have died from mpox. If you think you have contracted mpox, doctors recommend going to the hospital or calling your primary care physician. From there, treatment will be given, and quarantining will be recommended. There is a mpox vaccine available for people who are most at risk, like those who are immune compromised, HIV positive, or have cancer.

It just emphasizes that this is a disease that we have to keep an eye on because we still are seeing people infected with it, said Edwards. We're still seeing people die with it. That potential always exists."

COVID-19 cases are also on the rise again statewide. Gov. Mike DeWine tested positive for COVID-19 Tuesday morning, which marks his third time testing positive.

It is absolutely something to worry about and we don't currently have a vaccine that's active against the current circulating strength, Edwards added. They're still in production for the fall. So, it's a little unfortunate that the spike is coming before the vaccine is ready.

Doctors recommend regular hand washing and social distancing to avoid contracting COVID-19.

We Follow Through

Want us to continue to follow through on a story? Let us know.

Originally posted here:

COVID-19 and mpox cases on the rise in Northeast Ohio - News 5 Cleveland WEWS

Beyond COVID-19: the promise of next-generation coronavirus vaccines – Nature.com

August 22, 2024

Ghattas, M., Dwivedi, G., Lavertu, M. & Alameh, M. G. Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines (Basel) 9, https://doi.org/10.3390/vaccines9121490 (2021).

Beverley, P. C. Immunology of vaccination. Br. Med. Bull. 62, 1528 (2002).

Article CAS PubMed Google Scholar

Tyrrell, D. A. & Bynoe, M. L. Cultivation Of A Novel Type Of Common-Cold Virus In Organ Cultures. Br. Med. J. 1, 14671470 (1965).

Article CAS PubMed PubMed Central Google Scholar

Hamre, D. & Procknow, J. J. A new virus isolated from the human respiratory tract. Proc. Soc. Exp. Biol. Med. 121, 190193 (1966).

Article CAS PubMed Google Scholar

van der Hoek, L. et al. Identification of a new human coronavirus. Nat. Med. 10, 368373 (2004).

Article PubMed PubMed Central Google Scholar

Woo, P. C. et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79, 884895 (2005).

Article CAS PubMed PubMed Central Google Scholar

Zhong, N. S. et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, Peoples Republic of China, in February, 2003. Lancet 362, 13531358 (2003).

Article CAS PubMed PubMed Central Google Scholar

Zaki, A. M., Van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. & Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 18141820 (2012).

Article CAS PubMed Google Scholar

Ye, Z. W. et al. Zoonotic origins of human coronaviruses. Int. J. Biol. Sci. 16, 16861697 (2020).

Article CAS PubMed PubMed Central Google Scholar

Xie, X. et al. Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine. Cell Rep. 41, 111729 (2022).

Article CAS PubMed PubMed Central Google Scholar

Liu, Y. et al. Neutralizing Activity of BNT162b2-Elicited Serum. N. Engl. J. Med. 384, 14661468 (2021).

Article PubMed Google Scholar

Evans, J. P. et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci. Transl. Med. 14, eabn8057 (2022).

Article CAS PubMed Google Scholar

Kurhade, C. et al. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Emerg. Microbes Infect. 11, 18281832 (2022).

Article CAS PubMed PubMed Central Google Scholar

Andrews, N. et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 386, 15321546 (2022).

Article CAS PubMed Google Scholar

Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657663 (2022).

Article CAS PubMed Google Scholar

Lau, J. J. et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat. Med. 29, 348357 (2023).

Article CAS PubMed PubMed Central Google Scholar

Bar-On, Y. M. et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N. Engl. J. Med. 385, 13931400 (2021).

Article CAS PubMed Google Scholar

Burckhardt, R. M., Dennehy, J. J., Poon, L. L. M., Saif, L. J. & Enquist, L. W. Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters. J. Virol. 96, e0197321 (2022).

Article PubMed Google Scholar

Corbett, K. S. et al. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccineboosted nonhuman primates. Science 374, 13431353 (2021).

Article CAS PubMed Google Scholar

Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell. Mol. Immunol. 17, 613620 (2020).

Article CAS PubMed PubMed Central Google Scholar

Premkumar, L. et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, https://doi.org/10.1126/sciimmunol.abc8413 (2020).

Chan, J. F. et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 9, 221236 (2020).

Article CAS PubMed PubMed Central Google Scholar

Sharifkashani, S. et al. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting. Eur. J. Pharmacol. 884, 173455 (2020).

Article CAS PubMed PubMed Central Google Scholar

Mao, T. et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 378, eabo2523 (2022).

Article CAS PubMed PubMed Central Google Scholar

Port, J. R. et al. Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters. Nat. Commun. 14, 6592 (2023).

Article CAS PubMed PubMed Central Google Scholar

Brown, C. M. et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morb. Mortal. Wkly Rep. 70, 10591062 (2021).

Article CAS PubMed PubMed Central Google Scholar

Singanayagam, A. et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect. Dis. 22, 183195 (2022).

Article CAS PubMed PubMed Central Google Scholar

Li, X. et al. Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. Emerg. Microbes Infect. 11, 18901899 (2022).

Article CAS PubMed PubMed Central Google Scholar

Sui, Y. et al. Adjuvanted subunit intranasal vaccine prevents SARS-CoV-2 onward transmission in hamsters. bioRxiv, 2024.2005.2013.593816, https://doi.org/10.1101/2024.05.13.593816 (2024).

McMahan, K. et al. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques. Nature 626, 385391 (2024).

Article CAS PubMed Google Scholar

Woo, P. C. Y. et al. ICTV Virus Taxonomy Profile: Coronaviridae 2023. J Gen Virol 104, https://doi.org/10.1099/jgv.0.001843 (2023).

Lai, M. M. & Cavanagh, D. The molecular biology of coronaviruses. Adv. Virus Res. 48, 1100 (1997).

Article CAS PubMed PubMed Central Google Scholar

Neuman, B. W. et al. A structural analysis of M protein in coronavirus assembly and morphology. J. Struct. Biol. 174, 1122 (2011).

Article CAS PubMed Google Scholar

de Groot, R. J. Structure, function and evolution of the hemagglutinin-esterase proteins of corona- and toroviruses. Glycoconj. J. 23, 5972 (2006).

Article PubMed PubMed Central Google Scholar

Woo, P. C. Y., Huang, Y., Lau, S. K. P. & Yuen, K. Y. Coronavirus genomics and bioinformatics analysis. Viruses 2, 18041820 (2010).

Article CAS PubMed PubMed Central Google Scholar

Haring, J. & Perlman, S. Mouse hepatitis virus. Curr. Opin. Microbiol 4, 462466 (2001).

Article CAS PubMed PubMed Central Google Scholar

Stohlman, S., Bergmann, C. & Perlman, S. (John Wiley & Sons, Ltd. New York, 1998).

Bradburne, A. F., Bynoe, M. L. & Tyrrell, D. A. Effects of a new human respiratory virus in volunteers. Br. Med J. 3, 767769 (1967).

Article CAS PubMed PubMed Central Google Scholar

Gupta, A. et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 26, 10171032 (2020).

Article CAS PubMed Google Scholar

He, J., Guo, Y., Mao, R. & Zhang, J. Proportion of asymptomatic coronavirus disease 2019: A systematic review and metaanalysis. J. Med. Virol. 93, 820830 (2021).

Article CAS PubMed Google Scholar

Ki, M. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. Epidemiology and health 42 (2020).

Nishiura, H. et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int. J. Infect. Dis. 94, 154155 (2020).

Article CAS PubMed PubMed Central Google Scholar

Gao, Z. et al. A systematic review of asymptomatic infections with COVID-19. J. Microbiol., Immunol. Infect. 54, 1216 (2021).

Article CAS PubMed Google Scholar

Sayampanathan, A. A. et al. Infectivity of asymptomatic versus symptomatic COVID-19. Lancet 397, 9394 (2021).

Article CAS PubMed Google Scholar

Khan, S. et al. COVID-19: Clinical aspects and therapeutics responses. Saudi Pharm. J. 28, 10041008 (2020).

Article CAS PubMed PubMed Central Google Scholar

Da Silva, E. et al. An adverse outcome pathway for lung surfactant function inhibition leading to decreased lung function. Curr. Res Toxicol. 2, 225236 (2021).

Article PubMed PubMed Central Google Scholar

Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 10331034 (2020).

Article CAS PubMed PubMed Central Google Scholar

Channappanavar, R. & Perlman, S. In Seminars in immunopathology. 529-539 (Springer).

Peiris, J. S. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 17671772 (2003).

Article CAS PubMed PubMed Central Google Scholar

Wong, C. K. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 136, 95103 (2004).

Article CAS PubMed PubMed Central Google Scholar

Kwok, K. O. et al. Epidemiology, clinical spectrum, viral kinetics and impact of COVID-19 in the Asia-Pacific region. Respirology 26, 322333 (2021).

Article PubMed PubMed Central Google Scholar

Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133146 (2023).

Article CAS PubMed PubMed Central Google Scholar

Villarreal, L. P. In Encyclopedia of Virology (Third Edition) (eds Brian W. J. Mahy & Marc H. V. Van Regenmortel) 174-184 (Academic Press, 2008).

Robson, F. et al. Coronavirus RNA proofreading: molecular basis and therapeutic targeting. Mol. cell 79, 710727 (2020).

Article CAS PubMed PubMed Central Google Scholar

Read more from the original source:

Beyond COVID-19: the promise of next-generation coronavirus vaccines - Nature.com

COVID-19 masks rising homicide toll on black men – News-Medical.Net

August 22, 2024

While the COVID-19 pandemic quickly reversed decades of progress in closing the gap between life expectancies for Black and white people in the United States, the disease's toll may have obscured the impact of another significant public health concern -; a sharp increase in homicide rates -; on the life expectancy of Black men, according to researchers at the University of WisconsinMadison.

In 2019, Black men in the U.S. were expected to live an average of 71.4 years, 5 years less than white men. Just one year later, life expectancy for Black men had plummeted to 67.7 years, while white men fell just a year and a half. That opened the gap between the two groups to 7.2 years, far higher than the gap was even 20 years earlier (6.6 years in 2000).

The pandemic period knocked out a huge amount of those gains in just one year's time. COVID played the larger role in that reversal -; especially because it was initially more deadly among non-white people -; but it was not the only important change going on. In 2020, we also saw the largest increase in homicide that we've ever recorded."

Michael Light, Professor,University of WisconsinMadison

His research lies at the intersection of criminology and demography.

The difference between the homicide rates for Black men and white men, in particular, also erased a decades-long shift toward parity.

Homicide rates peaked in the U.S. in the late 1980s and early '90s, then fell by more than half by 2014. They remained relatively stable until, from 2019 to 2020, homicides jumped up by 30%.

Black men fared worst among homicide victims, rising from 43.8 deaths per 100,000 men in 2019 to 61 per 100,000 in 2020. Over the same period, the rate of death by homicide for white men rose from 3.6 to 4.4 per 100,000.

According to an analysis published on August21st, 2024, in the journal,PLOS ONE by Light and UWMadison graduate student Karl Vachuska, the rising homicide rate was responsible for 26% of the increase in the life expectancy gap between Black and white men from 2019 to 2021.

Compared to COVID-19, homicides carried extra weight in life-expectancy calculations, in which younger deaths pull harder on the averages. Light and Vachuska found that, in 2020, when racial disparities in COVID-19 deaths were most acute, homicides contributed more to Black-white inequality in life expectancy among men than any other cause of death, including COVID-19.

"COVID deaths were concentrated among older people," Light says. "But while homicide still represents a small proportion of overall deaths in the United States, it has a disproportionate impact on life expectancy because it's mostly killing young men."

When COVID-19 vaccines became available and public health measures more commonplace, homicide's influence on the Black-white life expectancy gap grew more pronounced. In 2021, homicide rates continued to rise, though not as fast as the 2020 jump. But the COVID-19 mortality imbalance between Black and white lives vanished.

"There was still a severe difference in life expectance between Black and white men in 2021," Light says. "That gap declined only slightly from 2020, even though the racial differences in COVID outcomes completely disappeared."

The new study's results show just how much sway murders can have on even broad measures of public health.

"While COVID was new and particularly devastating, it wasn't hard to look at the shifts in life expectancy and say, 'OK, when we get a handle on COVID, this will turn around,'" Light says. "But that does some minimizing of other important factors that need to be near the top of the list when we consider preventable deaths. That's important when we decide where public health resources should be placed."

The good news is the U.S. had already found success curbing homicides for decades pre-pandemic, and crime statistics for 2022 and 2023 show a renewed decline in homicide rates.

"Within our lifetime, within easy living memory, we achieved marked decreases in homicide and marked declines in racial disparities in homicide that had very real impacts on mortality inequality," Light says. "We know that emphasis on this problem can make a difference. What we learned about the pandemic period helps us understand just how significant those differences can be."

Source:

Journal reference:

Light, M. T., et al. (2024) Increased homicide played a key role in driving Black-White disparities in life expectancy among men during the COVID-19 pandemic. PLOS One. doi.org/10.1371/journal.pone.0308105

Read more here:

COVID-19 masks rising homicide toll on black men - News-Medical.Net

NIH-funded study finds long COVID affects adolescents differently than younger children – National Institutes of Health (NIH) (.gov)

August 22, 2024

News Release

Wednesday, August 21, 2024

Adolescents were most likely to experience low energy/tiredness while children were most likely to report headache.

Scientists investigating long COVID in youth found similar but distinguishable patterns between school-age children (ages 6-11 years) and adolescents (ages 12-17 years) and identified their most common symptoms. The study, supported by the National Institutes of Health (NIH) and published in JAMA, comes from research conducted through the NIHs Researching COVID to Enhance Recovery (RECOVER) Initiative, a wide-reaching effort to understand, diagnose, treat, and prevent long COVID, a condition marked by symptoms and health problems that linger after an infection with SARS-CoV-2, the virus that causes COVID-19.

Children and adolescents were found to experience prolonged symptoms after SARS-CoV-2 infection in almost every organ system with most having symptoms affecting more than one system.

Most research characterizing long COVID symptoms is focused on adults, which can lead to the misperception that long COVID in children is rare or that their symptoms are like those of adults, said David Goff, M.D., Ph.D., division director for the Division of Cardiovascular Sciences at the NIHs National Heart, Lung, and Blood Institute. Because the symptoms can vary from child to child or present in different patterns, without a proper characterization of symptoms across the life span, its difficult to know how to optimize care for affected children and adolescents.

The observational study included 3,860 children and adolescents with a SARS-CoV-2 infection history at more than 60 sites across the United States between March 2022 and December 2023. A comparison group of 1,516 children and adolescents with no history of a SARS-CoV-2 infection were also included to disentangle whether prolonged symptoms of those who had experienced COVID-19 were related to SARS-CoV-2 itself or more broadly related to the effects of the pandemic.

Caregivers completed a comprehensive symptom survey that asked about 75 prolonged symptoms in all major body systems that occurred at least 90 days after an initial SARS-CoV-2 infection and lasted for at least a month. They also completed a survey asking for their perception of the childs overall health, physical health, and quality of life. The researchers then employed a commonly used statistical technique to identify which symptoms were best at differentiating participants who did and did not have history of SARS-CoV-2 infection. They identified combinations of symptoms distinct for each age group that together generated a long COVID research index, which indicates the likely condition of long COVID.

Researchers identified 18 prolonged symptoms that were more common in school-age children, including headache (57%), followed by trouble with memory or focusing (44%), trouble sleeping (44%), and stomach pain (43%). Other common symptoms in school-age children not included in the research index included body, muscle, and joint pain; daytime tiredness/sleepiness or low energy; and feeling anxious.

In adolescents, 17 symptoms were more common, including daytime tiredness/sleepiness or low energy (80%); body, muscle, or joint pain (60%); headaches (55%); and trouble with memory or focusing (47%). Feeling anxious and trouble sleeping were other commonly reported symptoms that were not included in the research index.

The symptoms that make up the research index are not the only symptoms a child may have and theyre not the most severe, but they are most predictive in determining who may have long COVID, said Rachel Gross, M.D., associate professor in the departments of pediatrics and population health at New York University Grossman School of Medicine and lead author on the study.

Fourteen symptoms overlapped between the age groups. Comparing previous research on long COVID in adults, the new study found that adults and adolescents had a greater overlap in symptoms, such as loss of or change in smell or taste. Researchers found less overlap between adults and school-age children, underscoring the importance of age-based long COVID research.

The study identified separate research indexes for school-age children and adolescents along with overlapping, but distinguishable symptom patterns in each group. Of the 751 school-age children that had COVID-19, 20% met the long COVID research index threshold. Of the 3,109 adolescent children with a history of SARS-CoV-2 infection, 14% met the research index threshold, though researchers noted that these numbers should not be used as measures of incidence in the general population, since their study may have included more children with long COVID than the overall population.

Scientists note that the research index provides a framework for looking at common symptoms for research purposes not necessarily as a guide for clinical care and will likely be refined as researchers study more children with and without long COVID.

Our next step is to study children ages 5 years and younger so we can better understand long COVID in the very young, said Gross.

In compliance with NIHs Data Sharing and Management Policy, a dataset containing RECOVER Pediatric Observational Cohort Study data collected through June 15, 2024 which includes data used for this publication will be released on NHLBI BioData Catalyst this fall.

Research reported in this press release was supported by NIH under award numbers OT2HL161841, OT2HL161847, and OT2HL156812. Additional support came from grant R01 HL162373. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. For more information on RECOVER, visit https://recovercovid.org.

HHS Long COVID Coordination:This work is a part of theNational Research Action Plan(PDF, 1.3 MB), a broader government-wide effort in response to thePresidential Memorandumdirecting the Secretary for the Department of Health and Human Services to mount a full and effective response to Long COVID. Led by Assistant Secretary for Health Admiral Rachel Levine, the Plan and its companionServices and Supports for Longer-term Impacts of COVID-19 report(PDF, 1.6 MB) lay the groundwork to advance progress in the prevention, diagnosis, treatment, and provision of services for individuals experiencing Long COVID.

About RECOVER:The National Institutes of Health Researching COVID to Enhance Recovery (NIH RECOVER) Initiative brings together clinicians, scientists, caregivers, patients, and community members to understand, diagnose, and treat long COVID. RECOVER has created one of the largest and most diverse groups of Long COVID study participants in the world. In addition, RECOVER clinical trials are testing potential interventions across five symptom focus areas. For more information, please visitrecoverCOVID.org.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Original post:

NIH-funded study finds long COVID affects adolescents differently than younger children - National Institutes of Health (NIH) (.gov)

Page 11234..1020..»